Animesh Pardanani

Dec 27, 2024 | onlinelibrary.wiley.com | Patricia Carey |Animesh Pardanani |Patrick Starlinger |Ayalew Tefferi

To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.

May 21, 2024 | onlinelibrary.wiley.com | Ayalew Tefferi |Animesh Pardanani |Naseema Gangat

EDITORIAL Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? Ayalew Tefferi,  Corresponding Author Ayalew Tefferi Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA Correspondence Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Jan 3, 2024 | onlinelibrary.wiley.com | Ayalew Tefferi |Animesh Pardanani |Naseema Gangat

CONFLICT OF INTEREST STATEMENT No conflicts of interest related to this review are declared. REFERENCES 1, , , et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140: 1200-1228. 2, , , et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol. 2022; 98: 166-179. doi:10.1002/ajh.26751 3, , , .

Jun 12, 2023 | pubmed.ncbi.nlm.nih.gov | Animesh Pardanani

May 22, 2023 | onlinelibrary.wiley.com | Animesh Pardanani